Sugi Predict

Sugi Predict / Compounds / SCHEMBL1541130

SCHEMBL1541130

SCHEMBL1541130

NS(=O)(=O)c1ccc(Br)cc1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 9/20 0.53
▸ CA1 P00915 6/20 0.53
▸ CA9 Q16790 6/20 0.53
▸ CA5A P35218 4/20 0.53
▸ CA12 O43570 3/20 0.53
▸ CA4 P22748 2/20 0.53
▸ CA6 P23280 2/20 0.53
▸ CA7 P43166 1/20 0.53
▸ CA14 Q9ULX7 1/20 0.53
▸ CA5B Q9Y2D0 1/20 0.53
▸ CNR2 P34972 1/20 0.44
▸ KDM1A O60341 2/20 0.44
▸ PFKFB3 Q16875 1/20 0.41
▸ FFAR1 O14842 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ LMNA P02545 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29744331 1.00 CA2 (0.53) CA2CA1CA9CA5ACA12
SCHEMBL30945237 0.81 PFKFB3 (0.41) CA2CA1CA9CA5ACA12
SCHEMBL29843259 0.81 TRPV4 (0.58) CA2CA1CA9CA5ACA12
SCHEMBL14100608 0.81 PFKFB3 (0.41) CA2CA1CA9CA5ACA12
SCHEMBL709661 0.81 PFKFB3 (0.41) CA2CA1CA9CA5ACA12
SCHEMBL695564 0.81 TRPV4 (0.58) CA2CA1CA9CA5ACA12
SCHEMBL10296146 0.81 PFKFB3 (0.41) CA2CA1CA9CA5ACA12
SCHEMBL27921944 0.79 CA12 (0.55) CA2CA1CA9CA5ACA12
SCHEMBL4638383 0.79 CA12 (0.59) CA2CA1CA9CA5ACA12
SCHEMBL9048102 0.79 CA1 (0.55) CA2CA1CA9CA5ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4034094-B1 PHOSPHODIESTERASE INHIBITORS AND USE ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) 2026-04-15 — — EP disclosed
CN-116574099-A Phosphodiesterase inhibitors and uses 南京征祥医药有限公司 2023-08-11 — — CN disclosed
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-06-13 — — US disclosed
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-06-13 — — US disclosed
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-06-13 — — US disclosed
US-20230014730-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-01-19 — — US disclosed
US-20230014730-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-01-19 — — US disclosed
CN-115151253-A Phosphodiesterase inhibitors and uses thereof 南京征祥医药有限公司 2022-10-04 — — CN disclosed
EP-4034094-A1 PHOSPHODIESTERASE INHIBITORS AND USE Nanjing Zhengxiang Pharmaceuticals Co., Ltd. (CN) 2022-08-03 — — EP disclosed
US-20220220114-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2022-07-14 — — US disclosed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 — — US disclosed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 — — EP disclosed
US-20070072860-A1 N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide ABBOTT LABORATORIES 2007-03-29 — — US disclosed
US-20070015787-A1 Apoptosis promoters ABBVIE INC. 2007-01-18 — — US disclosed
US-20060258657-A1 Apoptosis promoters ABBVIE INC. 2006-11-16 — — US disclosed
EP-1685119-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2006-08-02 — — EP disclosed
US-20060128706-A1 Apoptosis promoters ABBVIE INC. 2006-06-15 — — US disclosed
US-20050159427-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2005-07-21 — — US disclosed
WO-2005049593-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-06-02 — — WO disclosed
WO-2005049594-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-06-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128706-A1 Apoptosis promoters BAX, BCL2, API5 CA2 3537/4885CA1 2869/4885CA9 4554/4885
US-20070015787-A1 Apoptosis promoters BAX, BCL2, API5 CA2 3537/4885CA1 2869/4885CA9 4554/4885
US-20060258657-A1 Apoptosis promoters BAX, BCL2, API5 CA2 3537/4885CA1 2869/4885CA9 4554/4885
US-20050159427-A1 N-acylsulfonamide apoptosis promoters BAX, API5, CCAR2 CA2 4218/4885CA1 3146/4885CA9 4538/4885
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 CA2 236/4885CA1 1466/4885CA9 1446/4885
US-20070072860-A1 N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide BCL2A1, BAX, BCL2L1 CA2 2210/4885CA1 3170/4885CA9 4004/4885
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors ENPP1, ENPP3, PDE4A CA2 3011/4885CA1 4735/4885CA9 4116/4885
US-20220220114-A1 PHOSPHODIESTERASE INHIBITORS AND USE ENPP1, ENPP3, PDE4A CA2 2126/4885CA1 4390/4885CA9 3638/4885
US-20230014730-A1 PHOSPHODIESTERASE INHIBITORS AND USE ENPP1, ENPP3, PDE4A CA2 2126/4885CA1 4390/4885CA9 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.